@article{article_1514723, title={A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine}, journal={Türkiye Çocuk Hastalıkları Dergisi}, volume={19}, pages={38–42}, year={2025}, DOI={10.12956/tchd.1514723}, author={Polat, Merve Cansu and Işıklar Ekici, Mehveş and Kaplan, Melike Mehveş and Çelikel, Elif and Ekici Tekin, Zahide and Güngörer, Vildan and Karagöl, Cüneyt and Öner, Nimet and Öztürk, Didem and Özçelik, Emine and et al.}, keywords={Colchicine, Immunoglobulin A vasculitis, Leukocytoclastic vasculitis, Recurrence}, abstract={Objective: The aim of the this study was to evaluate immunoglobulin A vasculitis (IgAV) patients on colchicine therapy and determine the causative factors leading to the initiation and maintenance of colchicine. Material and Methods: This retrospective study was conducted receiving IgAV patients on colchicine at our clinic between January 2013 and June 2023. Demographic, clinical, and laboratory data of IgAV patients were obtained from their electronic medical records. Results: A total of 33 IgAV patients receiving colchicine, 20 (60.6%) males and 13 (39.4%) females, were included in the study. The mean age at diagnosis of IgAV was 111.6±45.5 months. Colchicine was initiated in 13 (39.4%) patients with persistent rash, 8 (24.2%) with severe gastrointestinal tract involvement, seven (21.2%) with generalized/severe rash, and five (15.2%) with recurrent IgAV. The median elapsed time to colchicine initiation was 30 (10.5-60) days. The median duration of colchicine usage was ten (IQR, 6-54) months. Colchicine treatment was discontinued in 14 patients after a median 6.5 (IQR, 3-11.2) months. At the last visit, 13 (39.4%) patients were receiving colchicine for familial Mediterranean fever (FMF), four (12.1%) for recurrent IgAV, and two (6.1%) for persistent rash. Conclusion: Colchicine should be kept in mind especially in the presence of severe, persistent or recurrent rash. Early initiation of colchicine treatment should be considered in IgAV patients with severe GI tract disease, especially in countries where FMF is common.}, number={1}, publisher={T.C. Sağlık Bakanlığı Ankara Şehir Hastanesi}